Italy's Alfasigma pens $690M deal for GSK itching drug awaiting FDA approval decision
Italy's Alfasigma pens $690M deal for GSK itching drug awaiting FDA approval decision
Contenu indisponible. Consultez la source originale.
Italy's Alfasigma pens $690M deal for GSK itching drug awaiting FDA approval decision
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.